Navigation Links
Prostate cancer prognosis hope
Date:10/30/2012

Scientists have discovered a molecular 'tell' in laboratory experiments that could help doctors determine the severity of a patient's prostate cancer.

Cancer of the prostate the most common male cancer in the UK presents in two distinct ways: a low-risk type, which may never cause any symptoms, and a high-risk form that needs treatment to prevent it spreading to other parts of the body.

Knowing which type of prostate cancer each patient has some 40,000 British men per year is therefore essential to ensuring they receive the correct treatment.

Lead researcher Dr Angeliki Malliri, from the University of Manchester's Paterson Institute for Cancer Research, said: "Prognosis tells, or biomarkers, give doctors an indication of how a patient will fare after treatment. In prostate cancer, biomarkers that help differentiate between the low-risk and high-risk types of cancer are crucial to decide if and what type of treatment a patient needs."

The study, funded by Cancer Research UK and published in the journal Nature Cell Biology, identified the protein β2-syntrophin as a new prognosis marker for prostate cancer. The team, part of the Manchester Cancer Research Centre (MCRC), discovered that the protein is involved in establishing tight connections between cells, which are crucial for holding them together to maintain tissue structure and prevent tumours from spreading.

Co-author Dr Natalie Mack said: "We showed that when β2-syntrophin is lost from these cell-to-cell connections, the cells become disorganised and this is what happens in cells from prostate cancer samples, potentially helping them to spread.

"Our findings indicate that the loss of β2-syntrophin at cell-to-cell connections in the prostate is an indicator of prostate cancer progression and patients with reduced levels of this protein at these cell-to-cell connections are more likely to have a recurrence of their cancer after treatment."

The authors say their results suggest that β2-syntrophin is a new prognosis marker in prostate cancer and that it should be further explored to distinguish between low- and high-risk level disease. Improved understanding and use of prognosis markers is essential to help guide clinical decisions and to ensure that patients get the best type of treatment for their type of cancer.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "To treat prostate cancer more effectively, we need to understand more about how the disease develops and how to recognise more advanced types. This research provides another piece of the puzzle and further work will confirm whether this molecule could be useful in making better predictions about prostate cancer."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Proton therapy treatment preserves quality of life for men with prostate cancer
2. For many prostate cancer patients, Web sites are too difficult to read
3. Viagra Can Help Prostate Cancer Patients Maintain Sex Lives: Study
4. Drop in testosterone tied to prostate cancer recurrence
5. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
6. First web-based prostate cancer database launches
7. Lab Contamination Behind Debunked Link Between Virus, Prostate Cancer
8. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
9. Cloned receptor paves way for new breast and prostate cancer treatment
10. Drug Used to Prevent Prostate Cancer Wont Lower Quality of Life
11. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... autologous fat (adipose) transfer systems announces the issuance of United States Patent Number ... for its adipose filtration technology. The '398 and '324 patents cover methods ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to ... surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one ... world, Allergan is bringing a newly defined structure to the aesthetics market. Dr. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, ... Friday, July 28. , Increased FDA scrutiny and growing demands to track and ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “Nana Nana Boo ... importance of being kind to others. “Nana Nana Boo Boo” is the creation of ... man. , Published by Christian Faith Publishing, Michael Rush’s new book presents the ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... provider of education and training standards for healthcare treatment providers, offers healthcare ... Certification: the iaedp™ Core Curriculum. , Presented as either online or as ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... founder of Echenberg Institute, is announcing a new safe and effective at-home ... and other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, ... ... ... start-up company, VuVatech LLC, fills a void in the women,s wellness market ...
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
Breaking Medicine Technology: